Prediction and personalised treatment of atrial fibrillation—stroke prevention: consolidated position paper of CVD professionals

EPMA Journal

Christoph A Karle³  Karl-Heinz Kuck²  Roland Richard Tilz²  Bettina Zippel-Schultz¹  Giang Duong³  Thomas M Helms¹ 

[1] German Foundation for Chronically Ill, 21149 Hamburg, 90762 Fürth, Germany;Hanseatic Heart Centre, Asklepios Hospital St. Georg, 20099 Hamburg, Germany;Medical Practice For Diagnostics, Hohenlohe, 74653 Künzelsau, Germany

关键词: Horizon 2020;    Diabetes mellitus;    Healthcare economy;    Epi/genetic predisposition;    Catheter ablation;    Risk factors;    Stroke;    Atrial fibrillation;    Cardiovascular disease;    Predictive preventive personalised medicine;   

Others  :  1136553
DOI  :  10.1186/1878-5085-5-15

 received in 2014-04-28, accepted in 2014-07-24,  发布年份 2014

【 摘 要 】

Atrial fibrillation (AF) is one of the major morbidity and health economic factors in Europe and often associated with several co-morbidities. This paper (1) underlines the importance of highly professional AF management utilising a multi-disciplinary expertise, especially considering the role of AF regarding the stroke risk and prevention, (2) demonstrates the consolidated position of CVD professionals and (3) emphasises those research aspects that could deepen the understanding of the emergence and the treatment of AF and therefore helps to provide a personalised preventive and more effective management of AF. Specialised calls are considered for that within the new European Programme ‘Horizon 2020’.

【 授权许可】

   
2014 Helms et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH: Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31(19):2369-2429.
• [2]Wattigney WA, Mensah GA, Croft JB: Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2006, 108(6):711-716.
• [3]Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJL: Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014, 129(8):837-847.
• [4]Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV: Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004, 90(3):286-292.
• [5]Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Muller-Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dorr M, Ozaki K, Roberts JD, Smith JG, Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, et al.: Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012, 44(6):670-675.
• [6]Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive preventive and personalised medicine. EPMA J 2012, 3:14. BioMed Central Full Text
• [7]Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, Bailleul C, Bax J, Benninger G, Blomstrom-Lundqvist C, Boersma L, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Casadei B, Clemens A, Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, Gillis A, Gulizia M, Hack G, Haegeli L, Hatem S, Georg Hausler K, et al.: Personalized management of atrial fibrillation: proceedings from the fourth atrial fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013, 15(11):1540-1556.
• [8]Golubnitschaja O, Kinkorova J, Costigliola V: Predictive, preventive and personalised medicine as the hardcore of ‘Horizon 2020’: EPMA position paper. EPMA J 2014, 5(1):6. BioMed Central Full Text
• [9]Stewart S, Hart CL, Hole DJ, McMurray JJV: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001, 86(5):516-521.
• [10]Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U: Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373(9667):929-940.
• [11]Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TSM: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114(2):119-125.
• [12]Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, Newton‒Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ: Development of a risk score for atrial fibrillation (Framingham Heart Study): a community‒based cohort study. Lancet 2009, 373:739-745.
• [13]Schnabel RB, Aspelund T, Li G, Sullivan LM, Suchy‒Dicey A, Harris TB, Pencina MJ, D'Agostino RB Sr, Levy D, Kannel WB, Wang TJ, Kronmal RA, Wolf PA, Burke GL, Launer LJ, Vasan RS, Psaty BM, Benjamin EJ, Gudnason V, Heckbert SR: Validation of an atrial fibrillation risk algorithm in whites and African‒Americans. Arch Intern Med 2010, 170:1909-1917.
• [14]Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C: Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2011, 4(1):15-25.
• [15]Lowres N, Neubeck L, Redfern J, Ben Freedman S: Screening to identify unknown atrial fibrillation: a systematic review. Thromb Haemostasis 2013, 110(2):213-222.
• [16]Savelieva I, Camm AJ: Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electr 2000, 4(2):369-382.
• [17]Stewart S, Hart CL, Hole DJ, McMurray JJ: A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002, 113(5):359-364.
• [18]Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt G, Berger K, Ringelstein EB, Kirchhof P, Wersching H: Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008, 29(17):2125-2132.
• [19]Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994, 271(11):840-844.
• [20]Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH: Subclinical atrial fibrillation and the risk of stroke. New Engl J Med 2012, 366(2):120-129.
• [21]Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, Jarouse J, Brillman J, Murali S, Gupta R: Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 2008, 71(21):1696-1701.
• [22]Benn Cristiansen C: Impact of AF on stroke risk eliminated with multiple risk factors. Amsterdam ESC Congress; 2013. URL: http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/prevention-ischaemic-stroke-risk-factors-atrial-fibrillation.aspx webcite. Accessed 07.04.2014
• [23]Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, Lewalter T, Camm JA, Singer DE: Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014, 35(8):508-516.
• [24]Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146(12):857-867.
• [25]Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJM, Tijssen JGP, Crijns HJGM: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. New Engl J Med 2002, 347(23):1834-1840.
• [26]Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347(23):1825-1833.
• [27]Waldo AL: A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J 2006, 151(4):771-778.
• [28]The AFFIRM Investigators: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004, 109(12):1509-1513. doi:10.1161/01.CIR.0000121736. 16643.11
• [29]Noheria A, Kumar A, Wylie JV Jr, Josephson ME: Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008, 168(6):581-586.
• [30]Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, Hocini M, Extramiana F, Sacher F, Bordachar P, Klein G, Weerasooriya R, Clementy J, Haissaguerre M: Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008, 118(24):2498-2505.
• [31]Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Köktürk B, Konstantinidou M, Metzner A, Fuernkranz A, Kuck KH: Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010, 122(23):2368-2377.
• [32]Tilz RR, Rillig A, Thum AM, Arya A, Wohlmuth P, Metzner A, Mathew S, Yoshiga Y, Wissner E, Kuck KH, Ouyang F: Catheter ablation of long-standing persistent atrial fibrillation—5-year outcomes of the Hamburg sequential ablation strategy. JACC 2012, 60(19):1921-1929.
• [33]Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G: Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF. Eur Heart J 2009, 30(24):2969-2977c.
• [34]Quinn FR, Gladstone D: Screening for undiagnosed atrial fibrillation in the community. Curr Opin Cardiol 2014, 29(1):28-35.
• [35]Deif B, Lowres N, Freedman SB: Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. Int J Cardiol 2013, 164(3):371-372.
• [36]Engdahl J, Andersson L, Mirskaya M, Rosenqvist M: Stepwise screening of atrial fibrillation in a 75-year-old population implications for stroke prevention. Circulation 2013, 127(8):930-937.
• [37]Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. New Engl J Med 1998, 339(10):659-666.
• [38]Rossillo A, Bonso A, Themistoclakis S, Riccio G, Madalosso M, Corrado A, De Piccoli B, Raviele A: Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. J Cardiovasc Med 2008, 9(1):51-55.
• [39]Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, Mallender C, Anderson JL, Muhlestein B, Lappe DL, Day JD: Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013, 10(9):1272-1277.